• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Curetis N.V.

Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques. To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering many countries across Europe, the Middle East and Asia. *

 

	Start	2015-11-01 established
	Group	Curetis (Group)
	Predecessor	Curetis AG
	Industry	Unyvero molecular diagnostics platform
	Industry 2	Unyvero P50™ pneumonia cartridge
	Person	Schacht, Oliver (Curetis 201012– CEO before Epigenomics CFO)
	Person 2	Boos, Andreas (Curetis 200812– Managing Director)
	Region	Amsterdam
	Country	Netherlands
	City	n. a. Amsterdam
		Address record changed: 2015-11-15
Basic data	Employees	C: 51 to 100 (2019-04-01)
	Currency	EUR
	Annual sales	1,419,000 (revenue, consolidated (2018) 2018-12-31)
	Profit	-23,745,000 (2018-12-31)
	Cash	7,800,000 (2019-06-30)
		* Document for �About Section�: Curetis N.V.. (4/12/16). "Press Release: Curetis Publishes Full-year 2015 Financial Results and Introduces 2016 Guidance". Amsterdam & Holzgerlingen.
		Record changed: 2019-08-13

Advertisement

More documents for Curetis (Group)

• [1] Curetis N.V.. (1/14/20). "Press Release: Curetis Launches Unyvero LRT Panel for BAL Specimens in the U.S.". Amsterdam, Holzgerlingen & San Diego, CA....
• [2] OpGen, Inc.. (10/28/19). "Press Release: OpGen Announces Closing of $9.4 Million Underwritten Public Offering". Gaithersburg, MD....
• [3] Curetis N.V.. (10/28/19). "Press Release: Curetis Group Company Ares Genetics Launches AI-powered Molecular Antibiotic Susceptibility Test". Vienna & Holzgerlingen....
• [4] OpGen, Inc.. (10/23/19). "Press Release: OpGen Announces Pricing of $9.4 Million Underwritten Offering". Gaithersburg, MD....
• [5] Curetis N.V.. (9/16/19). "Press Release: Curetis Group Subsidiary Ares Genetics Signs R&D and Option Agreement with Leading Global IVD Corporation". Holzgerlingen & Vienna....
• [6] Curetis N.V.. (9/4/19). "Press Release: Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses". Gaithersburg, MD, Amsterdam & Holzgerlingen....
• [7] Curetis N.V.. (8/12/19). "Press Release: Curetis Retains H.C. Wainwright & Co. as Strategic Advisor". Amsterdam & Holzgerlingen....
• [8] Curetis N.V.. (8/8/19). "Press Release: Curetis Group Company Ares Genetics Launches Service Laboratory for NGS-based Molecular Drug Resistance Testing". Vienna & Holzgerlingen....
• [9] Curetis N.V.. (8/1/19). "Press Release: Curetis Elects Share Settlement for Excess Entitlement Under First Tranche of Yorkville Convertible Notes". Amsterdam, San Diego, CA & Holzgerlingen....
• [10] Curetis N.V.. (7/30/19). "Press Release: Curetis and Ako Med Ink Distribution Agreement Covering Four Countries in CEE Region". Amsterdam, San Diego, CA & Holzgerlingen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2020. Made in Germany.